| __timestamp | Supernus Pharmaceuticals, Inc. | Takeda Pharmaceutical Company Limited |
|---|---|---|
| Wednesday, January 1, 2014 | 5758000 | 520990000000 |
| Thursday, January 1, 2015 | 8423000 | 535405000000 |
| Friday, January 1, 2016 | 11986000 | 558755000000 |
| Sunday, January 1, 2017 | 15215000 | 495921000000 |
| Monday, January 1, 2018 | 15356000 | 659690000000 |
| Tuesday, January 1, 2019 | 16660000 | 1089764000000 |
| Wednesday, January 1, 2020 | 52459000 | 994308000000 |
| Friday, January 1, 2021 | 75061000 | 1106846000000 |
| Saturday, January 1, 2022 | 87221000 | 1244072000000 |
| Sunday, January 1, 2023 | 83779000 | 1431505000000 |
| Monday, January 1, 2024 | 1431505000000 |
Unlocking the unknown
In the ever-evolving pharmaceutical industry, cost efficiency is a critical metric for success. This analysis delves into the cost of revenue trends for Takeda Pharmaceutical Company Limited and Supernus Pharmaceuticals, Inc. from 2014 to 2023. Takeda, a global leader, consistently shows a substantial cost of revenue, peaking at approximately 1.43 trillion in 2023, reflecting its expansive operations. In contrast, Supernus, a smaller player, demonstrates a more modest cost structure, with a peak of around 87 million in 2022. Over the decade, Takeda's cost of revenue increased by about 175%, while Supernus saw a staggering 1,400% rise, highlighting its rapid growth trajectory. Notably, 2024 data for Supernus is missing, indicating potential reporting delays. This comparison underscores the diverse strategies and scales of operation within the pharmaceutical sector, offering insights into how companies manage their financial efficiencies.
Comparing Cost of Revenue Efficiency: Novo Nordisk A/S vs Takeda Pharmaceutical Company Limited
Cost of Revenue Comparison: Sanofi vs Supernus Pharmaceuticals, Inc.
Cost of Revenue Comparison: Takeda Pharmaceutical Company Limited vs Xenon Pharmaceuticals Inc.
Cost Insights: Breaking Down Takeda Pharmaceutical Company Limited and HUTCHMED (China) Limited's Expenses
Comparing Cost of Revenue Efficiency: Takeda Pharmaceutical Company Limited vs Mesoblast Limited
Cost of Revenue Trends: Takeda Pharmaceutical Company Limited vs Travere Therapeutics, Inc.
Comparing Cost of Revenue Efficiency: Takeda Pharmaceutical Company Limited vs Xencor, Inc.
Cost of Revenue Trends: Takeda Pharmaceutical Company Limited vs BioCryst Pharmaceuticals, Inc.
Catalent, Inc. vs Supernus Pharmaceuticals, Inc.: Efficiency in Cost of Revenue Explored
Cost of Revenue: Key Insights for Veracyte, Inc. and Supernus Pharmaceuticals, Inc.
Cost of Revenue: Key Insights for ACADIA Pharmaceuticals Inc. and Supernus Pharmaceuticals, Inc.
Cost Insights: Breaking Down Supernus Pharmaceuticals, Inc. and Agios Pharmaceuticals, Inc.'s Expenses